{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T21:47:54Z","timestamp":1791668874264,"version":"4.3.4"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T00:00:00Z","timestamp":1726185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100020558","name":"Labex Iron","doi-asserted-by":"publisher","award":["ANR-11-LABX-18\u201301"],"award-info":[{"award-number":["ANR-11-LABX-18\u201301"]}],"id":[{"id":"10.13039\/100020558","id-type":"DOI","asserted-by":"publisher"}]},{"name":"RHU OPERANDI","award":["ANR-21-RHUS-0012"],"award-info":[{"award-number":["ANR-21-RHUS-0012"]}]},{"name":"SIRIC ILIAD","award":["INCa-DGOS-INSERM\/ITMO Cancer_18011"],"award-info":[{"award-number":["INCa-DGOS-INSERM\/ITMO Cancer_18011"]}]},{"DOI":"10.13039\/501100002915","name":"Fondation pour la recherche m\u00e9dicale","doi-asserted-by":"publisher","award":["FDM202006011156"],"award-info":[{"award-number":["FDM202006011156"]}],"id":[{"id":"10.13039\/501100002915","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Nucl Med Mol Imaging"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00259-024-06918-0","type":"journal-article","created":{"date-parts":[[2024,9,13]],"date-time":"2024-09-13T08:12:40Z","timestamp":1726215160000},"page":"730-743","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Survival impact of [225Ac]Ac-DOTATOC alpha-therapy in a preclinical model of pancreatic neuroendocrine tumor liver micrometastases"],"prefix":"10.1007","volume":"52","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2278-0488","authenticated-orcid":false,"given":"Alexandre","family":"Lugat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Chouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Chocteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathilde","family":"Esnault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Marionneau-Lambot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Gouard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9ric","family":"Frampas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Faivre-Chauvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Bourgeois","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfred","family":"Morgenstern","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Bruchertseifer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Ch\u00e9rel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7oise","family":"Kraeber-Bod\u00e9r\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Ansquer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00eblle","family":"Gaschet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,13]]},"reference":[{"key":"6918_CR1","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","volume":"3","author":"A Dasari","year":"2017","unstructured":"Dasari A, Shen C, Halperin D, Zhao B, Zhou S, Xu Y, et al. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States. JAMA Oncol. 2017;3:1335\u201342.","journal-title":"JAMA Oncol"},{"key":"6918_CR2","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0960-0760(92)90184-K","volume":"43","author":"JC Reubi","year":"1992","unstructured":"Reubi JC, Laissue J, Krenning E, Lamberts SW. Somatostatin receptors in human cancer: incidence, characteristics, functional correlates and clinical implications. J Steroid Biochem Mol Biol. 1992;43:27\u201335.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"6918_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.mce.2007.12.002","volume":"286","author":"M Volante","year":"2008","unstructured":"Volante M, Rosas R, All\u00eca E, Granata R, Baragli A, Muccioli G, et al. Somatostatin, cortistatin and their receptors in tumours. Mol Cell Endocrinol. 2008;286:219\u201329.","journal-title":"Mol Cell Endocrinol"},{"key":"6918_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/S0140-6736(89)91258-0","volume":"1","author":"EP Krenning","year":"1989","unstructured":"Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet Lond Engl. 1989;1:242\u20134.","journal-title":"Lancet Lond Engl"},{"key":"6918_CR5","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/0016-5085(93)91066-Q","volume":"105","author":"H Scher\u00fcbl","year":"1993","unstructured":"Scher\u00fcbl H, B\u00e4der M, Fett U, Hamm B, Schmidt-Gayk H, Koppenhagen K, et al. Somatostatin-receptor imaging of neuroendocrine gastroenteropancreatic tumors. Gastroenterology. 1993;105:1705\u20139.","journal-title":"Gastroenterology"},{"key":"6918_CR6","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1007\/s00259-007-0450-1","volume":"34","author":"I Buchmann","year":"2007","unstructured":"Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Sch\u00e4fer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617\u201326.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6918_CR7","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1007\/s00261-015-0409-9","volume":"40","author":"TA Hope","year":"2015","unstructured":"Hope TA, Pampaloni MH, Nakakura E, VanBrocklin H, Slater J, Jivan S, et al. Simultaneous 68Ga-DOTA-TOC PET\/MRI with gadoxetate disodium in patients with neuroendocrine tumor. Abdom Imaging. 2015;40:1432\u201340.","journal-title":"Abdom Imaging"},{"key":"6918_CR8","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","volume":"31","author":"M Pavel","year":"2020","unstructured":"Pavel M, \u00d6berg K, Falconi M, Krenning EP, Sundin A, Perren A, et al. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2020;31:844\u201360.","journal-title":"Ann Oncol"},{"key":"6918_CR9","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors. N Engl J Med. 2017;376:125\u201335.","journal-title":"N Engl J Med"},{"key":"6918_CR10","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1007\/s00259-011-1902-1","volume":"38","author":"L Bodei","year":"2011","unstructured":"Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with 177Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6918_CR11","doi-asserted-by":"publisher","first-page":"e457","DOI":"10.1097\/RLU.0000000000001816","volume":"42","author":"S Ballal","year":"2017","unstructured":"Ballal S, Yadav MP, Damle NA, Sahoo RK, Bal C. Concomitant 177Lu-DOTATATE and Capecitabine Therapy in Patients With Advanced Neuroendocrine Tumors: A Long-term-Outcome, Toxicity, Survival, and Quality-of-Life Study. Clin Nucl Med. 2017;42:e457.","journal-title":"Clin Nucl Med"},{"key":"6918_CR12","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00259-014-2893-5","volume":"42","author":"L Bodei","year":"2015","unstructured":"Bodei L, Kidd M, Paganelli G, Grana CM, Drozdov I, Cremonesi M, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. Eur J Nucl Med Mol Imaging. 2015;42:5\u201319.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6918_CR13","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1016\/S1470-2045(21)00572-6","volume":"22","author":"JR Strosberg","year":"2021","unstructured":"Strosberg JR, Caplin ME, Kunz PL, Ruszniewski PB, Bodei L, Hendifar A, et al. 177Lu-Dotatate plus long-acting octreotide versus high-dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22:1752\u201363.","journal-title":"Lancet Oncol"},{"key":"6918_CR14","doi-asserted-by":"publisher","unstructured":"\u00a0Targeted Alpha Therapy Working Group, Parker C, Lewington V, Shore N, Kratochwil C, Levy M, Lind\u00e9n O, Noordzij W, Park J, Saad F. Targeted alpha therapy, an emerging class of cancer agents: a review. JAMA Oncol. 2018;4(12):1765\u201372. https:\/\/doi.org\/10.1001\/jamaoncol.2018.4044","DOI":"10.1001\/jamaoncol.2018.4044"},{"key":"6918_CR15","first-page":"1467","volume":"47","author":"M Cremonesi","year":"2006","unstructured":"Cremonesi M, Ferrari M, Bodei L, Tosi G, Paganelli G. Dosimetry in Peptide Radionuclide Receptor Therapy: A Review. J Nucl Med. 2006;47:1467\u201375.","journal-title":"J Nucl Med"},{"key":"6918_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11523-018-0550-9","volume":"13","author":"M Makvandi","year":"2018","unstructured":"Makvandi M, Dupis E, Engle JW, Nortier FM, Fassbender ME, Simon S, et al. Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations. Target Oncol. 2018;13:189\u2013203.","journal-title":"Target Oncol"},{"key":"6918_CR17","doi-asserted-by":"publisher","first-page":"906","DOI":"10.3390\/pharmaceutics13060906","volume":"13","author":"R Eychenne","year":"2021","unstructured":"Eychenne R, Ch\u00e9rel M, Haddad F, Gu\u00e9rard F, Gestin J-F. Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The \u201cHopeful Eight.\u201d Pharmaceutics. 2021;13:906.","journal-title":"Pharmaceutics"},{"key":"6918_CR18","doi-asserted-by":"publisher","unstructured":"Ballal S, Yadav MP, Bal C, Sahoo RK, Tripathi M. Broadening horizons with 225Ac-DOTATATE targeted alpha therapy for gastroenteropancreatic neuroendocrine tumour patients stable or refractory to 177Lu-DOTATATE PRRT: first clinical experience on the efficacy and safety. Eur J Nucl Med Mol Imaging. 2020;47(4):934\u201346. https:\/\/doi.org\/10.1007\/s00259-019-04567-2","DOI":"10.1007\/s00259-019-04567-2"},{"key":"6918_CR19","doi-asserted-by":"publisher","unstructured":"Kratochwil C, Apostolidis L, Rathke H, Apostolidis C, Bicu F, Bruchertseifer F, Choyke PL, Haberkorn U, Giesel FL, Morgenstern A. Dosing 225Ac-DOTATOC in patients with somatostatin-receptor-positive solid tumors: 5-year follow-up of hematological and renal toxicity. Eur J Nucl Med Mol Imaging. 2021;49(1):54\u201363. https:\/\/doi.org\/10.1007\/s00259-021-05474-1","DOI":"10.1007\/s00259-021-05474-1"},{"key":"6918_CR20","doi-asserted-by":"publisher","first-page":"3555","DOI":"10.1158\/1078-0432.CCR-07-4647","volume":"14","author":"M Miederer","year":"2008","unstructured":"Miederer M, Henriksen G, Alke A, Mossbrugger I, Quintanilla-Martinez L, Senekowitsch-Schmidtke R, et al. Preclinical Evaluation of the \u03b1-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors. Clin Cancer Res. 2008;14:3555\u201361.","journal-title":"Clin Cancer Res"},{"key":"6918_CR21","doi-asserted-by":"publisher","unstructured":"Tafreshi NK, Pandya DN, Tichacek CJ, Budzevich MM, Wang Z, Reff JN, Engelman RW, Boulware DC, Chiappori AA, Strosberg JR, Ji H, Wadas TJ, El-Haddad G, Morse DL. Preclinical evaluation of [225Ac]Ac-DOTA-TATE for treatment of lung neuroendocrine neoplasms. Eur J Nucl Med Mol Imaging. 2021;48(11):3408\u201321. https:\/\/doi.org\/10.1007\/s00259-021-05315-1","DOI":"10.1007\/s00259-021-05315-1"},{"key":"6918_CR22","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1159\/000443167","volume":"103","author":"M Pavel","year":"2016","unstructured":"Pavel M, O\u2019toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS Consensus Guidelines Update for the Management of Distant Metastatic Disease of Intestinal, Pancreatic, Bronchial Neuroendocrine Neoplasms (NEN) and NEN of Unknown Primary Site. Neuroendocrinology. 2016;103:172\u201385.","journal-title":"Neuroendocrinology"},{"key":"6918_CR23","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.30400","volume":"139","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in neuroendocrine tumors. Int J Cancer. 2016;139:2679\u201386.","journal-title":"Int J Cancer"},{"key":"6918_CR24","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/MNM.0b013e328341b268","volume":"32","author":"E Frampas","year":"2011","unstructured":"Frampas E, Maurel C, Thedrez P, Remaud-Le Sa\u00ebc P, Faivre-Chauvet A, Barbet J. The intraportal injection model for liver metastasis: advantages of associated bioluminescence to assess tumor growth and influences on tumor uptake of radiolabeled anti-carcinoembryonic antigen antibody. Nucl Med Commun. 2011;32:147\u201354.","journal-title":"Nucl Med Commun"},{"key":"6918_CR25","doi-asserted-by":"publisher","first-page":"14S","DOI":"10.1177\/0192623312438736","volume":"40","author":"KS Frazier","year":"2012","unstructured":"Frazier KS, Seely JC, Hard GC, Betton G, Burnett R, Nakatsuji S, et al. Proliferative and nonproliferative lesions of the rat and mouse urinary system. Toxicol Pathol. 2012;40:14S-86S.","journal-title":"Toxicol Pathol"},{"key":"6918_CR26","doi-asserted-by":"publisher","first-page":"27502","DOI":"10.18632\/oncotarget.25514","volume":"9","author":"F Foubert","year":"2018","unstructured":"Foubert F, Gouard S, Sa\u00ef-Maurel C, Ch\u00e9rel M, Faivre-Chauvet A, Goldenberg DM, et al. Sensitivity of pretargeted immunoPET using 68Ga-peptide to detect colonic carcinoma liver metastases in a murine xenograft model: Comparison with 18FDG PET-CT. Oncotarget. 2018;9:27502\u201313.","journal-title":"Oncotarget"},{"key":"6918_CR27","doi-asserted-by":"crossref","unstructured":"Lavilla-Alonso S, Abo-Ramadan U, Halavaara J, Escutenaire S, Tatlisumak T, Saksela K, et al. Optimized Mouse Model for the Imaging of Tumor Metastasis upon Experimental Therapy. PLoS ONE [Internet]. 2011 [cited 2021 Apr 20];6. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC3207818\/","DOI":"10.1371\/journal.pone.0026810"},{"key":"6918_CR28","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.acra.2012.09.030","volume":"20","author":"P Pandit","year":"2013","unstructured":"Pandit P, Johnston SM, Qi Y, Story J, Nelson R, Johnson GA. The utility of microCT and MRI in the assessment of longitudinal growth of liver metastases in a preclinical model of colon carcinoma. Acad Radiol. 2013;20:430\u20139.","journal-title":"Acad Radiol"},{"key":"6918_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.gcb.2007.12.018","volume":"32","author":"O Beuf","year":"2008","unstructured":"Beuf O, Lartizien C, Milot L, Babo\u00ef L, Roche C, Langlois J-B, et al. Multimodal imaging for the detection and characterization of liver lesions in a mouse model of neuroendocrine tumor. Gastroent\u00e9rologie Clin Biol. 2008;32:32\u201340.","journal-title":"Gastroent\u00e9rologie Clin Biol"},{"key":"6918_CR30","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1159\/000111502","volume":"87","author":"L Stelter","year":"2008","unstructured":"Stelter L, Amthauer H, Rexin A, Pinkernelle J, Schulz P, Michel R, et al. An Orthotopic Model of Pancreatic Somatostatin Receptor (SSTR)-Positive Tumors Allows Bimodal Imaging Studies Using 3T MRI and Animal PET-Based Molecular Imaging of SSTR Expression. Neuroendocrinology. 2008;87:233\u201342.","journal-title":"Neuroendocrinology"},{"key":"6918_CR31","first-page":"6818","volume":"27","author":"JH Dam","year":"2022","unstructured":"Dam JH, Langkj\u00e6r N, Baun C, Olsen BB, Nielsen AY, Thisgaard H. Preparation and Evaluation of [18F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [68Ga]Ga-DOTA\/NOTA-NOC. Mol Basel Switz. 2022;27:6818.","journal-title":"Mol Basel Switz"},{"key":"6918_CR32","first-page":"228","volume":"61","author":"TL Andersen","year":"2020","unstructured":"Andersen TL, Baun C, Olsen BB, Dam JH, Thisgaard H. Improving Contrast and Detectability: Imaging with [55Co]Co-DOTATATE in Comparison with [64Cu]Cu-DOTATATE and [68Ga]Ga-DOTATATE. J Nucl Med Off Publ Soc Nucl Med. 2020;61:228\u201333.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"6918_CR33","doi-asserted-by":"publisher","unstructured":"Cal-Gonzalez J, Vaquero JJ, Herraiz JL, P\u00e9rez-Liva M, Soto-Montenegro ML, Pe\u00f1a-Zalbidea S, Desco M, Ud\u00edas JM. Improving PET quantification of small animal [68Ga]DOTA-Labeled PET\/CT studies by using a CT-based positron range correction. Mol Imaging Biol. 2018;20(4):584\u201393. https:\/\/doi.org\/10.1007\/s11307-018-1161-7","DOI":"10.1007\/s11307-018-1161-7"},{"key":"6918_CR34","first-page":"199S","volume":"46","author":"DA Mulford","year":"2005","unstructured":"Mulford DA, Scheinberg DA, Jurcic JG. The Promise of Targeted \u03b1-Particle Therapy. J Nucl Med. 2005;46:199S-204S.","journal-title":"J Nucl Med"},{"key":"6918_CR35","first-page":"795","volume":"59","author":"C Kratochwil","year":"2018","unstructured":"Kratochwil C, Bruchertseifer F, Rathke H, Hohenfellner M, Giesel FL, Haberkorn U, et al. Targeted \u03b1-Therapy of Metastatic Castration-Resistant Prostate Cancer with 225Ac-PSMA-617: Swimmer-Plot Analysis Suggests Efficacy Regarding Duration of Tumor Control. J Nucl Med Off Publ Soc Nucl Med. 2018;59:795\u2013802.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"6918_CR36","first-page":"1049","volume":"51","author":"E Vegt","year":"2010","unstructured":"Vegt E, de Jong M, Wetzels JFM, Masereeuw R, Melis M, Oyen WJG, et al. Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. J Nucl Med Off Publ Soc Nucl Med. 2010;51:1049\u201358.","journal-title":"J Nucl Med Off Publ Soc Nucl Med"},{"key":"6918_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","volume":"30","author":"EJ Rolleman","year":"2003","unstructured":"Rolleman EJ, Valkema R, de Jong M, Kooij PPM, Krenning EP. Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine. Eur J Nucl Med Mol Imaging. 2003;30:9\u201315.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6918_CR38","first-page":"649","volume":"24","author":"T B\u00e4ck","year":"2009","unstructured":"B\u00e4ck T, Haraldsson B, Hultborn R, Jensen H, Johansson ME, Lindegren S, et al. Glomerular Filtration Rate After Alpha-Radioimmunotherapy with 211At-MX35-F(ab\u2032)2: A Long-Term Study of Renal Function in Nude Mice. Cancer Biother Radiopharm. 2009;24:649\u201358.","journal-title":"Cancer Biother Radiopharm"},{"key":"6918_CR39","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13550-016-0240-5","volume":"6","author":"HS Chan","year":"2016","unstructured":"Chan HS, Konijnenberg MW, Daniels T, Nysus M, Makvandi M, de Blois E, et al. Improved safety and efficacy of 213Bi-DOTATATE-targeted alpha therapy of somatostatin receptor-expressing neuroendocrine tumors in mice pre-treated with l-lysine. EJNMMI Res. 2016;6:83.","journal-title":"EJNMMI Res"},{"key":"6918_CR40","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/0360-3016(91)90171-Y","volume":"21","author":"B Emami","year":"1991","unstructured":"Emami B, Lyman J, Brown A, Cola L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol. 1991;21:109\u201322.","journal-title":"Int J Radiat Oncol"},{"key":"6918_CR41","doi-asserted-by":"publisher","first-page":"1692","DOI":"10.2967\/jnumed.117.202903","volume":"59","author":"Y Menda","year":"2018","unstructured":"Menda Y, Madsen MT, O\u2019Dorisio TM, Sunderland JJ, Watkins GL, Dillon JS, et al. 90Y-DOTATOC Dosimetry-Based Personalized Peptide Receptor Radionuclide Therapy. J Nucl Med. 2018;59:1692\u20138.","journal-title":"J Nucl Med"},{"key":"6918_CR42","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1007\/s00259-008-0778-1","volume":"35","author":"L Bodei","year":"2008","unstructured":"Bodei L, Cremonesi M, Ferrari M, Pacifici M, Grana CM, Bartolomei M, et al. Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factors. Eur J Nucl Med Mol Imaging. 2008;35:1847\u201356.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6918_CR43","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1007\/s00259-024-06681-2","volume":"51","author":"G Liubchenko","year":"2024","unstructured":"Liubchenko G, B\u00f6ning G, Zacherl M, Rumiantcev M, Unterrainer LM, Gildehaus FJ, et al. Image-based dosimetry for [225Ac]Ac-PSMA-I&T therapy and the effect of daughter-specific pharmacokinetics. Eur J Nucl Med Mol Imaging. 2024;51:2504\u201314.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"6918_CR44","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1088\/1361-6560\/ad5c37","volume":"69","author":"H Koniar","year":"2024","unstructured":"Koniar H, Wharton L, Ingham A, Rodr\u00edguez-Rodr\u00edguez C, Kunz P, Radchenko V, et al. In vivoquantitative SPECT imaging of actinium-226: feasibility and proof-of-concept. Phys Med Biol. 2024;69:15.","journal-title":"Phys Med Biol"},{"key":"6918_CR45","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1007\/s00259-012-2330-6","volume":"40","author":"JJ Zaknun","year":"2013","unstructured":"Zaknun JJ, Bodei L, Mueller-Brand J, Pavel ME, Baum RP, H\u00f6rsch D, et al. The joint IAEA, EANM, and SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2013;40:800\u201316.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["European Journal of Nuclear Medicine and Molecular Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00259-024-06918-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00259-024-06918-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,14]],"date-time":"2025-01-14T21:19:05Z","timestamp":1736889545000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00259-024-06918-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,13]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["6918"],"URL":"https:\/\/doi.org\/10.1007\/s00259-024-06918-0","relation":{},"ISSN":["1619-7070","1619-7089"],"issn-type":[{"value":"1619-7070","type":"print"},{"value":"1619-7089","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,13]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were carried out in accordance with the European directive 2010\/63\/EU on the protection of laboratory animals and its transposition into French law (decree n\u20002013\u2013118) and were conducted on the Experimental Therapeutic Unit platform (SFR Fran\u00e7ois Bonamy, IRS-UN, University of Nantes, license number: D44-278).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving animals"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"No potential conflicts of interest relevant to this article exist.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}